

Media Release

## Smith & Nephew and Synthes Settle Patent Dispute for Trochanteric Fixation Nails

*Memphis, TN (USA) and West Chester, PA (USA), February 20, 2008*

**Smith & Nephew plc** and **Synthes, Inc.** (SWX: SYST.VX) jointly announce the settlement of a patent dispute involving trochanteric fixation nails. Smith & Nephew has agreed to license its patents to Synthes and to dissolve the injunction against the Synthes TFN devices for an undisclosed amount.

### **Synthes: A leading medical device company**

Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

### **For further information please contact**

Giljan Eisner, Investor Relations, Synthes, Inc.

Phone +41 32 720 47 45, Fax +41 32 720 48 11, e-mail [ir.info@synthes.com](mailto:ir.info@synthes.com)

<http://www.synthes.com/>

### **Restrictions subject to US-Securities Law**

SYNTHES MANAGEMENT BELIEVES CERTAIN STATEMENTS IN THIS PRESS RELEASE MAY CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS INCLUDE BUT ARE NOT LIMITED TO THOSE WITH RESPECT TO THE POTENTIAL FOR SYNTHES TO OFFER NEW PRODUCTS AND MARKET EXISTING ONES, AS WELL AS THE EXPECTED SALES AND SALES GROWTH OF SYNTHES. THESE STATEMENTS ARE MADE ON THE BASIS OF MANAGEMENT'S VIEWS AND ASSUMPTIONS REGARDING FUTURE EVENTS AND BUSINESS PERFORMANCE AS OF THE TIME THE STATEMENTS ARE MADE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED. SUCH DIFFERENCES MAY RESULT FROM THE ABILITY OF SYNTHES TO SUCCESSFULLY DEVELOP AND INTRODUCE NEW PRODUCTS AND SERVICES AND MARKET EXISTING PRODUCTS AND SERVICES IN A COMPETITIVE MARKETPLACE AND CHANGES IN THE ECONOMIC CONDITIONS THAT MAY AFFECT THE PERFORMANCE OF THE OPERATIONS OF SYNTHES. IN ADDITION, CHANGES IN COMPETITIVE CONDITIONS AND REGULATORY DEVELOPMENTS MAY AFFECT FUTURE BUSINESS PERFORMANCE, AND CHANGING MARKET CONDITIONS MAY AFFECT THE VALUATION OF SYNTHES SECURITIES.

IN ADDITION, IT SHOULD BE NOTED THAT PAST FINANCIAL AND OPERATIONAL PERFORMANCE OF THE COMPANY IS NOT NECESSARILY INDICATIVE OF FUTURE FINANCIAL AND OPERATIONAL PERFORMANCE. SYNTHES UNDERTAKES NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

THE SECURITIES OF SYNTHES, INC. HAVE BEEN OFFERED AND SOLD OUTSIDE THE UNITED STATES AND HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED ("THE SECURITIES ACT"). SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S OF THE SECURITIES ACT), EXCEPT PURSUANT TO A REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OR UNDER AN APPLICABLE EXEMPTION UNDER THE SECURITIES ACT. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. THE SYNTHES SECURITIES ARE DEEMED "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT.